The FDA has released draft guidance that aims to clear up how drug developers can use alternative testing – but that doesn’t mean animal testing in the US is over.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing ...
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate ...
Officials with the FDA have released a draft guidance that aims to help drug developers validate new approach methodologies (NAMs) that can be used in place of animal testing. Based on human-centric ...
FDA’s NAM framework emphasizes context of use, human biological relevance, technical characterization, and fit-for-purpose ...
A research team at NYU Langone Health and Sage Bionetworks has been awarded a $25 million grant to establish the ...
The US Food and Drug Administration on Wednesday issued a draft guidance to help companies reduce animal studies of ...
The FDA has released a draft guidance outlining how drug developers can validate new approach methodologies (NAMs) as alternatives to animal testing in preclinical drug development. The guidance, ...
Drug developers will be able to use alternatives to animal testing and possibly get new products to market faster under draft guidance issued Wednesday by the FDA. In a press release, officials said ...
The Trump administration is redoubling its efforts to phase out animal testing in drug development using new approach methodologies.
Health authorities in the U.S. are continuing their move away from animal testing in drug development, with the FDA signaling an openness to new approaches that haven’t been validated and the National ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results